Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

Drug Metabolism and Disposition

Volumn 31, Issue 3, 2003, Pages 243-249

  Kalgutkar, Amit S ^a   Taylor, Timothy J ^a   Venkatakrishnan, Karthik ^a   Isin, Emre M ^b  

^a PFIZER INC   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL]PYRIDINIUM; ANTIDEPRESSANT AGENT; BUSPIRONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; GLUCURONIDE; HALOPERIDOL; NEFAZODONE; NEUROLEPTIC AGENT; NORFLUOXETINE; PYRIDINIUM DERIVATIVE; REDUCED HALOPERIDOL; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; CATALYST; DRUG ACTIVATION; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; IC 50; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; NEUROTOXICITY; PRIORITY JOURNAL; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; MICROSOMES, LIVER; PYRIDINIUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 0037369521     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.3.243     Document Type: Article

References (35)

1. Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, and Caputi AP (1997) Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 35:335-339.
2. Avent KM, Riker RR, Fraser GL, Van der Schyf CJ, Usuki E, and Pond SM (1997) Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci 61:2383-2390.
3. Barbhaiya RH, Shukla U, Greene DS, Breuel H-P, and Midha K (1996) Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 16:26-34.
4. Bloomquist J, King E, Wright A, Mytilneou C, Kimura K, Castagnoli K, and Castagnoli N Jr (1994) 1-Methyl-4-phenypyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270:822-830.
5. Craig DA (1993) The Cheng-Prusoff relationship: something lost in the translation. Trends Pharmacol Sci 14:89-91.
6. Eyles DW, Avent KM, Stedman TJ, and Pond SM (1997) Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 60:529-534.
7. Eyles DW and Pond SM (1992) Stereospecific reduction of haloperidol in human tissues. Biochem Pharmacol 44:867-871.
8. Fang J, McKay G, Song J, Remillrd A, Li X, and Midha K (2001) In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab Dispos 12:1638-1643.
9. Forsman A, Folsch G, Larsson M, and Ohman R (1977) The metabolism of haloperidol in man. Curr Ther Res Clin Exp 21:606-617.
10. Javaid JI, Janicak PG, Sharma RP, Leach AM, Davis JM, and Wang Z (1996) Prediction of haloperidol steady-state levels in plasma after a single test dose. J Clin Psychopharmacol 16:45-50.
11. Kalgutkar AS, Dalvie DK, Castagnoli N Jr, and Taylor TJ (2001) Interactions of nitrogencontaining xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 14:1139-1162.
12. Kudo S and Ishizaki T (1999) Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37:435-456.
13. Kudo S and Odomi M (1998) Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 54:253-259.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP 3A promoters and characterization of the genetic basis of polymorphic CYP 3A5 expression. Nat Genet 27:383-391.
15. Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, and Liston TE (2001) Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 29:1403-1409.
16. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, and Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132.
17. Llerena A, Alm C, Dahl M-L, Ekqvist B, and Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:92-97.
18. Nemeroff CB, DeVane CL, and Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
19. Oida T, Terauchi Y, Yoshida K, Kagemoto A, and Sekine Y (1989) Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 19:781-793.
20. Pan LP, De Vriendt C, and Belpaire FM (1998) In vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of haloperidol. Pharmacogenetics 8:383-389.
21. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP 3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 66:288-294.
22. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, and Shader RI (1995) N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 275:592-597.
23. Someya T, Shibasaki M, Noguchi T, Takahashi S, and Inaba T (1992) Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. Psychopharmacology 12:169-174.
24. Subramanyam B, Pond SM, Eyles DW, Whiteford HA, Fouda HG, and Castagnoli N Jr (1991b) Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 181:573-578.
25. Subramanyam B, Woolf T, and Castagnoli N Jr (1991a) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4:123-128.
26. Ulrich S, Wurthmann C, Brosz M, and Meyer FP (1998) The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 34:227-263.
27. Usuki E, Pearce R, Parkinson A, and Castagnoli N Jr (1996) Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 9:800-806.
28. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, and Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353.
29. Van der Schyf CJ, Castagnoli K, Usuki E, Fouda HG, Rimoldi JM, and Castagnoli N Jr (1994) Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem Res Toxicol 7:281-285.
30. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
31. Viala A, Aymard N, Leyris A, and Caroli F (1996) Pharmacoclinical correlations in depressed schizophrenic patients treated by haloperidol decanoate and fluoxetine. Therapie 51:19-25.
32. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, and Shader RI (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation and P450-3A4 inhibitory actions. Psychopharmacology (Berl) 145:113-122.
33. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, and Shader RI (1998) Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacology 140:293-299.
34. Wright AM, Bempong ML, Kirby RL, and Bloomquist JR (1998) Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788:215-222.
35. Yao C and Levy RH (2002) Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data. J Pharm Sci 91:1923-1935.